Experience

Davis Polk advised the joint lead managers and joint bookrunners in connection with an issuance of $500 million Regulation S offering by Yancoal International Resources Development Co.,…

Davis Polk advised the underwriters in connection with an SEC-registered offering of $700 million aggregate principal amount of 3.750% notes due 2030 by AngloGold Ashanti Holdings plc,…

Davis Polk advised the underwriter in connection with a block trade of 663,394 shares of Class A common stock of Bandwidth Inc. by VIP II Nominees Limited (for the benefit of Vitruvian…

On November 4, 2020, Chief Judge Leonard P. Stark of the U.S. District Court for the District of Delaware granted with prejudice a motion to dismiss filed by Davis Polk on behalf of…

Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A/Regulation S offering by Finance of America Funding LLC of $350 million aggregate…

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by NovoCure Limited of $575 million aggregate principal amount of its 0.000%…

Davis Polk advised the underwriters in connection with a $500 million Regulation S only offering by China SCE Group Holdings Limited of its 7.000% senior notes due 2025. China SCE Group…

Davis Polk advised the underwriters in the initial public offering of JW (Cayman) Therapeutics Co. Ltd on the Hong Kong Stock Exchange and an international offering and listing in reliance…

Davis Polk advised the representatives of the underwriters in connection with the $345 million initial public offering of 14,375,000 shares of common stock of Atea Pharmaceuticals, Inc.,…

Davis Polk advised Coloplast on its acquisition of Nine Continents Medical, an early stage company pioneering an implantable tibial nerve stimulation treatment for over-active bladder. The…